SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.

zacks.com - 2026-07-13 11:01:12

FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.

zacks.com - 2026-07-13 04:26:03

PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.

zacks.com - 2026-07-09 05:56:06

Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

zacks.com - 2026-07-08 11:30:13

Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.

zacks.com - 2026-07-07 12:15:34

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

accessnewswire.com - 2026-07-01 16:05:00

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

accessnewswire.com - 2026-06-16 16:00:00

Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, leveraging major pharma partners for commercialization without heavy infrastructure costs. ICOTYDE's FDA approval and rusfertide's Priority Review position PTGX for milestone payments, high-margin royalties, and a capital-light revenue model. PTGX maintains a strong balance sheet with $620M+ cash, a funding runway through 2028, and episodic profitability, reducing financing risk.

seekingalpha.com - 2026-06-13 08:46:00

Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 12:12:20

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.

accessnewswire.com - 2026-06-01 07:05:00

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.

accessnewswire.com - 2026-05-28 07:05:00

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

zacks.com - 2026-05-22 11:05:22

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

zacks.com - 2026-05-12 12:56:17

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible for up to $580 million in future milestone payments Rusfertide NDA accepted and granted Priority Review by FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026 Protagonist exercised its rusfertide opt-out right under the Takeda collaboration on April 28, triggering a $200 million opt-out fee payable to the Company; eligible for additional $200 million opt-out and $75 million milestone payments upon NDA approval, sales milestones of up to $775 million and worldwide royalties ranging from 14% to 29% PN-881 (oral IL-17 antagonist peptide) Phase 1 study completion by mid-2026 and Phase 2 initiation anticipated by year-end; PN-477sc and PN-477o (sc and oral triple GLP/GIP/GICG agonist) Phase 1 initiation expected in mid-2026 and Q1 2027, respectively Cash, cash equivalents and marketable securities of $620 million as of March 31, 2026, anticipated to provide cash runway through at least 2028 NEWARK, CA / ACCESS Newswire / May 5, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked a series of landmark achievements for Protagonist, highlighted by the U.S. approval of ICOTYDE, FDA granting Priority Review for rusfertide, and advancement of our highly differentiated and fully-owned peptides PN-881 and PN-477," said Dinesh V.

accessnewswire.com - 2026-05-05 16:05:00

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 million milestone payment, bringing total potential cash tied to the opt-out election and approval to $475 million Protagonist becomes eligible for up to $975 million in milestone payments and tiered royalties ranging from 14% to 29% on worldwide net sales NEWARK, CA / ACCESS Newswire / April 28, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or the "Company") today announced that it has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under its worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV). By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible to receive up to $400 million in opt-out payments, consisting of $200 million payable upon the opt-out election and a further $200 million payable upon FDA approval of rusfertide for the treatment of adults with PV.

accessnewswire.com - 2026-04-28 09:05:00

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

accessnewswire.com - 2026-04-16 16:05:00